Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at Leerink Partners

Leerink Partners started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report published on Tuesday, MarketBeat reports. The firm issued an outperform rating and a $44.00 price objective on the stock.

A number of other brokerages also recently issued reports on ORKA. Lifesci Capital started coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set an outperform rating and a $41.00 price objective on the stock. Wedbush started coverage on shares of Oruka Therapeutics in a research note on Wednesday, September 4th. They set an outperform rating and a $40.00 price objective on the stock. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research note on Friday, September 13th. They set a buy rating and a $40.00 price objective on the stock. Finally, TD Cowen started coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set a buy rating on the stock. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of Buy and an average target price of $41.25.

Oruka Therapeutics Trading Up 0.7 %

ORKA stock opened at $25.00 on Tuesday. Oruka Therapeutics has a 52 week low of $18.72 and a 52 week high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.